BIOLOGICAL RATIONALE FOR PLANNING THE TREATMENT OF BREAST CANCER


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The 12th International Breast Cancer Conference in St. Gallen (2011) adopted new approaches to planning its therapy. A simplified immunohistochemical classification was proposed as a useful alternative to a gene classification. The definition of the subtypes of breast cancer significantly alleviates the determination of indications for therapy because the subtypes are themselves characterized by many risk factors and predictors, which were separately used in earlier guidelines.

全文:

受限制的访问

作者简介

V. Semlglazov

NN. Petrov Oncology Research Institute

Email: vsemiglazov@mail.ru
Professor MD, Corresponding Member of the Russian Academy of Medical Sciences Saint Petersburg

V. Semlglazov

2Acad. I.P. Pavlov Saint Petersburg Medical University

Professor MD Saint Petersburg

R. Paltuyev

NN. Petrov Oncology Research Institute

Candidate of Medical Sciences Saint Petersburg

T. Semiglazova

NN. Petrov Oncology Research Institute

Candidate of Medical Sciences Saint Petersburg

G. Dashyan

NN. Petrov Oncology Research Institute

Candidate of Medical Sciences Saint Petersburg

参考

  1. Cheang M., Chia S., Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal В breast cancer // J. Natl. Cancer. Inst. - 2009; 101: 736-50.
  2. Hammond M., Hayes D., Wolff A. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer // J. Clin. Oncol. - 2011; 29: 1152-62.
  3. Perou C., Sorlie T., Eisen M. et al. Molecular portraits of human breast tumours // Nature. - 2000; 406: 747-52.
  4. Piccart-Gebhart M., Procter M., Leyland-Jones В. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer // N. Engl. J. Med. - 2005; 353: 1659-72.
  5. Romond E., Perez E., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer // N. Engl. J. Med. -2005; 353: 1673-84.
  6. Viale G., Regan M., Mastropasqua M. et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for nodenegative breast cancer // J. Natl. Cancer. Inst. - 2008; 100: 207-12.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2012
##common.cookie##